Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of TD-9855 in Patients With Fibromyalgia (FM)

Next Previous
Search
Trial Profile

A Phase 2 Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of TD-9855 in Patients With Fibromyalgia (FM)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ampreloxetine (Primary)
  • Indications Fibromyalgia
  • Focus Therapeutic Use
  • Sponsors Theravance; Theravance Biopharma

Most Recent Events

  • 27 Aug 2020 Results of pooled analysis of data from two phase I and two Phase II studies, assessing the pharmacokinetics of once-daily oral ampreloxetine and provide dose recommendations for clinical development, published in the Clinical Pharmacokinetics
  • 03 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 29 Jan 2014 Planned End Date changed from 1 Nov 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top